Amgen News - LARVOL Sigma

«1 2...57 58 59 60 616263 64 65 66 67...858 859 »

|||||||||| astegolimab (RG 6149) / Amgen, Roche
Pharmacokinetics (PK) of the anti-ST2 monoclonal antibody, astegolimab (PS-10; Poster board no. 17) - May 31, 2024 - Abstract #ERS2024ERS_3009;
P2, P2b, P
Baseline sST2 levels were comparable in healthy volunteers and patients with asthma or COPD. PK in patients with COPD will be confirmed in pivotal studies (NCT05037929; NCT05595642).

|||||||||| GB-0895 / Generate Biomedicines
A long-acting high affinity anti-TSLP antibody (GB-0895) for severe asthma identified leveraging a proprietary machine learning platform (PS-10; Poster board no. 13) - May 31, 2024 - Abstract #ERS2024ERS_3005;
Conclusions GB-0895 has the potential for best-in-class dosing for patients with severe asthma. A phase 1 dose escalation trial in asthma patients is underway.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma (PS-9; Poster board no. 7) - May 31, 2024 - Abstract #ERS2024ERS_2979;
A phase 1 dose escalation trial in asthma patients is underway. ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Can we trust the SOURCE ? Real world maintenance OCS reduction outcomes in complex severe asthmatics on Tezepelumab (PS-9; Poster board no. 6) - May 31, 2024 - Abstract #ERS2024ERS_2978;
ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma. Despite the findings of the SOURCE RCT, our study shows that in a real-world severe asthma cohort, 6 doses of Tezepelumab enabled 69% of patients to achieve ?50% mOCS dose reduction,with 46% being able to essentially taper off.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Pharmacokinetics, pharmacodynamics and safety of tezepelumab in children with asthma (PS-9; Poster board no. 5) - May 31, 2024 - Abstract #ERS2024ERS_2977;
P1
Despite the findings of the SOURCE RCT, our study shows that in a real-world severe asthma cohort, 6 doses of Tezepelumab enabled 69% of patients to achieve ?50% mOCS dose reduction,with 46% being able to essentially taper off. The PK, PD and safety after a single 70 mg dose of tezepelumab in children were as expected from previous studies in other age groups, supporting further development of tezepelumab for children with asthma.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab in eosinophilic granulomatosis with polyangiitis (EGPA) (PS-9; Poster board no. 4) - May 31, 2024 - Abstract #ERS2024ERS_2976;
Neither experienced an EGPA relapse. Conclusion In a first ever report of tezepelumab use in EGPA, we describe clinically important improvements in two patients with refractory EGPA.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
A comparison of T2 biomarker suppression with Tezepelumab in the real world and phase 3 NAVIGATOR study (PS-9; Poster board no. 3) - May 31, 2024 - Abstract #ERS2024ERS_2975;
In a RW severe asthma cohort, a large proportion of patients treated with tezepelumab continue to have evidence of T2 inflammation suggesting that other key drivers of IL-5 and IL-13 pathways remain active. The clinical significance requires further assessment.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Biomarkers and phenotyping: a holistic approach to asthma treatment with tezepelumab (PS-9; Poster board no. 2) - May 31, 2024 - Abstract #ERS2024ERS_2974;
P2, P3
The clinical significance requires further assessment. Changes in biomarker levels over 52 weeks were not associated with on-treatment AAER with tezepelumab treatment; however, changes in some biomarkers correlated with improvements in lung function, asthma symptoms and QoL.

|||||||||| AZD8630 / AstraZeneca, Amgen
Pharmacokinetics of AZD8630/AMG 104 inhaled anti-TSLP in healthy adults and asthma patients (PS-9; Poster board no. 1) - May 31, 2024 - Abstract #ERS2024ERS_2973;
P1
AZD8630/AMG 104 displayed dose proportional PK characteristics in the dose range studied and a half-life suitable for once-daily dosing. Together with low rates of immunogenicity following 4-weeks of dosing this data supports the ongoing development of AZD8630/AMG 104 as a first-in-class inhaled biologic treatment option for asthma patients.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE) (Lehar 3) - May 31, 2024 - Abstract #ERS2024ERS_2677;
P2
Together with low rates of immunogenicity following 4-weeks of dosing this data supports the ongoing development of AZD8630/AMG 104 as a first-in-class inhaled biologic treatment option for asthma patients. Tezepelumab delayed the time to first moderate or severe COPD exacerbation, overall and across BEC subgroups.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab in Real life setting: elucidating the clinical effectiveness, tolerability, and safety in severe asthma patients (PS-13; Poster board no. 5) - May 31, 2024 - Abstract #ERS2024ERS_2216;
No safety concerns were observed. Over the 6-months period, tezepelumab showed improvement in asthma control and FEV1 in patients with uncontrolled asthma.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
TSLP blocking modifies cross-talk between airway epithelium and macrophages reducing macrophage activation (A3) - May 31, 2024 - Abstract #ERS2024ERS_1916;
Tezepelumab interferes with this activation. The detection of oxidative stress by electrochemical sensors can open new avenues for evaluating epithelial damage and to identify patients eligible to alarmin targeted biologics.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Characteristics of responders and non-responders to Tezepelumab in a complex, real-world severe asthma population (PS-11; Poster board no. 17) - May 31, 2024 - Abstract #ERS2024ERS_1317;
The detection of oxidative stress by electrochemical sensors can open new avenues for evaluating epithelial damage and to identify patients eligible to alarmin targeted biologics. Whilst there was a statistically significant response to Tezepelumab in this real-world setting, there were no clear demographic or clinical characteristics that were predictive of a more favourable response to it, which clearly identifies an area for further study.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Relationship between FeNO suppression and Clinical Remission with Tezepelumab in Severe Asthma (PS-11; Poster board no. 11) - May 31, 2024 - Abstract #ERS2024ERS_1311;
Whilst there was a statistically significant response to Tezepelumab in this real-world setting, there were no clear demographic or clinical characteristics that were predictive of a more favourable response to it, which clearly identifies an area for further study. In a real-world cohort of SA patients, tezepelumab led to marked clinical responses in both biologic na

|||||||||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
RESOLVE-LUNG, a multinational, randomized, placebo-controlled Phase II trial of namilumab, an anti-GMCSF monoclonal antibody, in chronic pulmonary sarcoidosis: trial design and patient characteristics (A3) - May 31, 2024 - Abstract #ERS2024ERS_950;
P2
The majority of patients enrolled were above 50 years of age, male, Caucasian, and treated with OCS and/or IST, with methotrexate being the most commonly used IST. RESOLVE-LUNG, one of the largest Phase II trials in chronic sarcoidosis aims to investigate the efficacy and safety profile of namilumab in chronic pulmonary sarcoidosis.

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Blinatumomab-Induced Pneumonitis in a Pediatric Case in B-cell Acute Lymphoblastic Leukemia (PS-20; Poster board no. 15) - May 31, 2024 - Abstract #ERS2024ERS_677;
The onset of symptoms shortly after drug administration, the presence of septal thickening on CT suggestive of interstitial lung disease, and the rapid response to steroids imply a potential association with drug-induced pneumonitis. In patients receiving immunotherapy, after excluding infectious causes, it is important to consider drug-related interstitial lung diseases when both radiological and clinical features indicate such conditions.

|||||||||| Repatha (evolocumab) / Amgen, Astellas
Journal: Translocator Protein 18 kDa Tracer 18F-FDPA PET/CTA Imaging for the Evaluation of Inflammation in Vulnerable Plaques. (Pubmed Central) - May 31, 2024
18 New Zealand rabbits were divided into 3 groups: sham group A, VAP model group B, and evolocumab treatment group C. 18F-FDPA PET/CTA imaging was performed at 12, 16, and 24 weeks in all groups...This indicates a correlation between 18F-FDPA uptake, inflammation severity, and VAPs. The TSPO-targeted tracer 18F-FDPA shows specific uptake in macrophage-rich regions of atherosclerotic plaques, making it a valuable tool for assessing inflammation in VAPs.

|||||||||| ivabradine / Generic mfg.
Observational data, Journal, Adverse events: Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalization and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India. (Pubmed Central) - May 31, 2024
Overall, observations from the study results show that IVA?+?BB seems to be overall well tolerated in the study sample, with a somewhat smaller decrease in hospitalization and a delay in MACE events in the sample population enrolled in a tertiary care hospital in India. Further exploration in a larger sample is required concerning the Indian population.

|||||||||| vepdegestrant (ARV-471) / Arvinas, Pfizer
Preclinical, Journal, Combination therapy, Monotherapy: Oral estrogen receptor PROTAC (Pubmed Central) - May 31, 2024
Further exploration in a larger sample is required concerning the Indian population. Vepdegestrant achieved greater ER degradation in-vivo compared to fulvestrant, which correlated with improved tumor growth inhibition, suggesting vepdegestrant could be a more effective backbone ET for patients with ER+/HER2- breast cancer.

|||||||||| Stivarga (regorafenib) / Bayer
Journal, Metastases: COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma. (Pubmed Central) - May 31, 2024
Interestingly, rescue experiments show that the inhibition of the above aggressive features of resistant cells by COL5A2 loss is clearly alleviated by silencing of LIFR. Collectively, our results reveal that COL5A2 promotes the ability of regorafenib-resistant HCC cells to acquire a metastatic phenotype by attenuating LIFR expression and suggest that therapeutic regimens targeting the COL5A2/LIFR axis may be beneficial for HCC patients with therapeutic resistance.

|||||||||| Stivarga (regorafenib) / Bayer
Preclinical, Journal: Formulation, development and evaluation of hyaluronic acid-conjugated liposomal nanoparticles loaded with regorafenib and curcumin and their in vitro evaluation on colorectal cancer cell lines. (Pubmed Central) - May 31, 2024
Collectively, our results reveal that COL5A2 promotes the ability of regorafenib-resistant HCC cells to acquire a metastatic phenotype by attenuating LIFR expression and suggest that therapeutic regimens targeting the COL5A2/LIFR axis may be beneficial for HCC patients with therapeutic resistance. The IC50 of free REGO, CUR, REGO-LIPO, CUR-LIPO, REGO-LIPO-HA and CUR-LIPO-HA were 20.17

|||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Immune checkpoints: new insights into the pathogenesis of thyroid eye disease. (Pubmed Central) - May 31, 2024
This review will examine the overall pathogenic mechanism linked to the immune cells of TED and then discuss the latest research findings on the immunomodulatory role of ICs in the development and pathogenesis of TED. This will offer fresh perspectives on the study of pathogenesis and the identification of potential therapeutic targets.

|||||||||| Repatha (evolocumab) / Amgen, Astellas
Journal: PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety. (Pubmed Central) - May 31, 2024
Early use of evolocumab in AIS patients undergoing MT appeared to be safe and associated with better early functional outcomes. The potential benefit of the PCSK9 inhibitor shown here warrants further prospective studies.

||||||||||  inlexisertib (DCC-3116) / Ono Pharma
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors (clinicaltrials.gov) -  May 31, 2024
P1/2, N=173, Recruiting,  Sponsor: Deciphera Pharmaceuticals LLC
The potential benefit of the PCSK9 inhibitor shown here warrants further prospective studies. N=323 --> 173 | Trial completion date: Oct 2024 --> Aug 2028 | Trial primary completion date: Apr 2024 --> Aug 2027

|||||||||| Ibrance (palbociclib) / Pfizer
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review. (Pubmed Central) - May 31, 2024
In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.

|||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: How I treat newly diagnosed acute lymphoblastic leukemia. (Pubmed Central) - May 31, 2024
Such a strategy may allow the avoidance of systemic chemotherapy. The future role of allo-HCT in this context appears uncertain.

||||||||||  Stivarga (regorafenib) / Bayer
Trial completion, Real-world evidence, Real-world, Stroma, Metastases:  An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States (clinicaltrials.gov) -  May 31, 2024
P=N/A, N=136, Completed,  Sponsor: Bayer
The future role of allo-HCT in this context appears uncertain. Not yet recruiting --> Completed

|||||||||| Trial completion: SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (clinicaltrials.gov) - May 31, 2024
P1, N=68, Completed, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion date, Trial primary completion date, Adverse events, Metastases: Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (clinicaltrials.gov) - May 31, 2024
P4, N=53, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: May 2024 --> Feb 2025

||||||||||  rocatinlimab (KHK4083) / Amgen
New P1 trial:  A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants (clinicaltrials.gov) -  May 31, 2024
P1, N=230, Not yet recruiting,  Sponsor: Amgen

|||||||||| bortezomib / Generic mfg., ONX 0914 / Protalex, Amgen, M-3258 / EMD Serono
Review, Journal: The role of the immunoproteasome in cardiovascular disease. (Pubmed Central) - May 30, 2024
Furthermore, the immunoproteasome also serves nonimmune functions, such as maintaining protein homeostasis and regulating signalling pathways, and is involved in the pathophysiological processes of various cardiovascular diseases (CVDs). This review aims to provide a comprehensive summary of the current research on the involvement of the immunoproteasome in cardiovascular diseases, with the ultimate goal of identifying novel strategies for the treatment of these conditions.

|||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. (Pubmed Central) - May 30, 2024
In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%...In Ph+ ALL, the chemotherapy-free combinations of blinatumomab and ponatinib (or dasatinib) have become a new standard of care resulting in 3-year OS of 85% to 90%. Because the methotrexate-cytarabine courses were omitted in the nonchemotherapy regimens, central nervous system (CNS) relapses were noted, particularly in patients with a WBC count > 70

|||||||||| Tavneos (avacopan) / Amgen, Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
Journal: ANCA-associated vasculitis - Treatment Standard. (Pubmed Central) - May 30, 2024
There has been an increased attention on minimising the adverse effects of treatment and of understanding the epidemiology of co-morbidities in AAV. This review will focus on recent evidence from clinical trials, especially with respect to glucocorticoids, avacopan, plasma exchange, rituximab and mepolizumab, and their interpretation in the 2022 management recommendations by the European League of Associations of Rheumatology (EULAR).

|||||||||| ivabradine / Generic mfg.
Journal: Heart Rate Lowering for Coronary CTA with Ivabradine in End-Stage Liver Disease. (Pubmed Central) - May 30, 2024
This review will focus on recent evidence from clinical trials, especially with respect to glucocorticoids, avacopan, plasma exchange, rituximab and mepolizumab, and their interpretation in the 2022 management recommendations by the European League of Associations of Rheumatology (EULAR). No abstract available

|||||||||| Preclinical, Journal: Cold Storage Followed by Transplantation Induces Immunoproteasome in Rat Kidney Allografts: Inhibition of Immunoproteasome Does Not Improve Function. (Pubmed Central) - May 30, 2024
These results suggest that the pharmacological inhibition of immunoproteasome function during CS does not improve graft function or outcome. In light of these findings, future studies targeting immunoproteasomes during both CS and transplantation may define the role of immunoproteasomes on short- and long-term kidney transplant outcomes.

|||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal: Revolutionizing non-melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage. (Pubmed Central) - May 30, 2024
Other RTKIs were only employed in experimental investigations. Research indicates that RTKIs could potentially serve as a suitable alternative for elderly patients who are unable to undergo chemotherapy and radiotherapy.

|||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical, Clinical guideline, Review, Journal: Atraumatic splenic rupture secondary to granulocyte-colony stimulating factor medication exposure. (Pubmed Central) - May 30, 2024
An emergent trauma surgery consultation was placed, and he underwent embolization with an uneventful recovery. This case report highlights the need for a high index of suspicion for atraumatic splenic rupture in patients exposed to these types of granulocyte-colony stimulating factors.

||||||||||  Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date:  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) -  May 29, 2024
P3, N=244, Recruiting,  Sponsor: National Cancer Institute (NCI)
This case report highlights the need for a high index of suspicion for atraumatic splenic rupture in patients exposed to these types of granulocyte-colony stimulating factors. Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027

||||||||||  TTI-101 oral / Tvardi Therap
Trial completion, Metastases:  REVERT: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) -  May 29, 2024
P1/2, N=6, Completed,  Sponsor: Tvardi Therapeutics, Incorporated
Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027 Active, not recruiting --> Completed

||||||||||  AVZO-021 / Avenzo Therap
Enrollment change, Trial completion date, Trial primary completion date:  ARTS-021-1001: Study of AVZO-021 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  May 29, 2024
P1/2, N=430, Recruiting,  Sponsor: Avenzo Therapeutics, Inc.
Active, not recruiting --> Completed N=192 --> 430 | Trial completion date: Apr 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Jan 2028

||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Trial completion, Trial completion date, Mismatch repair:  Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (clinicaltrials.gov) -  May 29, 2024
P1, N=52, Completed,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=192 --> 430 | Trial completion date: Apr 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Jan 2028 Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024

||||||||||  dazodalibep (HZN-4920) / Amgen
Trial primary completion date:  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sj (clinicaltrials.gov) -  May 29, 2024
P3, N=510, Recruiting,  Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024 Trial primary completion date: Feb 2026 --> Jul 2026

|||||||||| BIOLOGIC AND TARGETED SYNTHETIC DRUGS MANAGEMENT IN RHEUMATOID ARTHRITIS AFTER IMPLEMENTATION OF A COMMUNITY OPTIMIZATION PROTOCOL () - May 29, 2024 - Abstract #EULAR2024EULAR_4504;
One out of four patients decreased the dose or increased the drug administration interval. Consequently, a considerable reduction in costs was observed.

|||||||||| Prolia (denosumab) / Amgen
SECONDARY PREVENTION OF OSTEOPOROSIS: CLINICAL AND FUNCTIONAL PROFILE OF ELDERLY PATIENTS WITH HIP FRACTURE () - May 29, 2024 - Abstract #EULAR2024EULAR_4447;
Previous fractures often go untreated, which leads to new fractures that compromise the patients' quality of life, independence and survival. Hip fractures show high rates of morbidity and mortality.

|||||||||| Prolia (denosumab) / Amgen, Edirol (eldecalcitol) / Roche, Taisho
MEASUREMENT OF 25(OH)VITAMIN D AND THE EFFECTIVENESS OF NUTRITIONAL GUIDANCE IN PATIENTS WITH RHEUMATIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_4439;
Patients were able to increase their 25(OH) D levels without medication with nutritional guidance. The effectiveness of denosumab and Ca/VD should be clarified in follow-up studies.

|||||||||| Prolia (denosumab) / Amgen
FRACTURE RISK FOLLOWING DENOSUMAB DISCONTINUATION IN THE ONCOLOGIC POPULATION: INCIDENCE AND RISK FACTORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4428;
OF occurred in 13% of patients after discontinuing DENO, a rate comparable to that observed in common osteoporosis. This OF rebound supports the ESMO recommendation to consider bisphosphonate therapy after discontinuing DENO.

|||||||||| Prolia (denosumab) / Amgen
FACTORS AFFECTING PERSISTENCE OF DENOSUMAB TREATMENT IN PATIENTS WITH OSTEOPOROSIS: A RETROSPECTIVE COHORT STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4426;
Denosumab treatment persistence is significantly influenced by patient's cognitive status, use of more than 5 drugs, and having received previous osteoporosis treatments. These factors should be considered when initiating long-term treatments, reevaluating the type of treatment, and reinforcing follow-up for these patients.

|||||||||| Prolia (denosumab) / Amgen
EVALUATING OSTEOPOROSIS AND RELEVANT FACTORS IN RHEUMATOLOGICAL PATIENTS RECEIVING GLUCOCORTICOID THERAPY () - May 29, 2024 - Abstract #EULAR2024EULAR_4423;
GIOP was significantly associated with age, disease duration, and steroid dose and duration. To avoid the development of GIOP, it is advised that GC be used in clinical practice at the lowest effective dose and for the shortest time feasible.

|||||||||| Prolia (denosumab) / Amgen
EFFECTS OF LONGTERM ORAL BISPHOSPHONATE THERAPY IN PATIENTS WITH OSTEOPOROSIS: WHAT DO WE DO NEXT? () - May 29, 2024 - Abstract #EULAR2024EULAR_4422;
A third of patients sustained further fractures whilst on treatment. There is no consensus on course of treatment after 10 years of bisphosphonates and study looks at clinical decision making for treatment continuation.

|||||||||| Tavneos (avacopan) / Amgen
SERUM C3/C4 LEVELS IN RENAL ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: PREDICTORS OF LUNG DISEASE AND WORSE PROGNOSIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4293;
Low C4 levels were associated with higher relapse rates and faster progression to dialysis, revealing that C4 activation impacts outcomes in AAV and that both classic and alternative complement pathways are involved. Combining low C3 and/or C4 levels identified patients at higher risk of acute dialysis requirement, independently of renal function at admission.



	Diseases Companies Products Productz Mechanisms of Action Sites